Research and Markets: Antifibrotic Pipeline - Potential Therapeutic Targets and Company Involvement Analysed.DUBLIN, Ireland -- Research and Markets (http://www.researchandmarkets.com/reports/c12557) has announced the addition of Stakeholder Perspectives: Liver Fibrosis/Cirrhosis - Point of No Return? to their offering. Chronic liver disease Chronic liver disease is a liver disease of slow process and persisting over a long period of time, resulting in a progressive destruction of the liver. It includes amongst others:
CDC - Control Data Corporation , National Center for Health Statistics National Center for Health Statistics (NCHS) is part of the Centers for Disease Control and Prevention (CDC), which is part of the United States Department of Health and Human Services. NCHS is the United States' principal health statistics agency. , 2004). Liver fibrosis is a clinically silent wound healing wound healing Physiology The repair of a wound Steps Inflammation, repair and closure, remodeling, final healing; repair of incisions may be either simple–'clean' wounds with little loss of tissue heal by 'primary intention', or 'dirty' wounds heal by process initiated in response to continuous insult to hepatic tissue. Globally, major causes are chronic HBV HBV hepatitis B virus. HBV abbr. hepatitis B virus and HCV HCV abbr. hepatitis C virus HCV 1 Hepatitis C virus, see there 2. Human coronavirus. See Coronavirus. infection along with the metabolic disorders NAFLD/NASH. Liver fibrosis, which is an outcome of persistent hepatic inflammation, if left unmanaged has serious long-term consequences for patient morbidity and mortality Morbidity and Mortality can refer to:
Increased vaccination and blood screening programs have reduced the incidence of HBV and HCV transmission in major Western markets, respectively. In spite of this, most experts agree that the natural history of both infections and increasing prevalence of obesity will contribute to a large cohort of advanced cirrhotic patients in 10-15 years. To date there are no approved antifibrotic agents for the management of fibrosis. Treatment is more focused on dealing with underlying conditions such as the use of antivirals for HBV/HCV and lifestyle changes for metabolic disorders. There is much debate regarding disease reversibility, optimum point of intervention and diagnostic strategy. This report provides: --In depth overview of current epidemiological data and sources regarding major underlying causes of liver fibrosis and cirrhosis --Expert assessment of current and long term drivers to patient pool suffering with fibrosis/cirrhosis --In depth analysis of underlying mechanisms of liver fibrosis, current patient flow and diagnostic techniques --Appraisal of antifibrotic pipeline and comment on potential therapeutic targets along with company involvement This will enable readers: --Understand long-term fibrosis/cirrhosis patient potential and potential market segmentation --Define the optimal target product profile for an antifibrotic agent --Understand current challenges and commercial opportunities within this potential epidemic For more information visit http://www.researchandmarkets.com/reports/c12557 |
|
||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion